Biotricity (BTCY) Stock Price, News & Analysis

Company Overview

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Key Stats

• Today's Range: $0.26 to $0.29
• 50-Day Range: $0.20 to $0.57
• 52-Week Range: $0.19 to $1.67
• Volume: 6,380 shs
• Average Volume: 77,185 shs
• Market Capitalization: $6.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biotricity Stock Analysis - MarketRank™

Biotricity scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biotricity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biotricity is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biotricity is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.73% of the outstanding shares of Biotricity have been sold short.

Short Interest Ratio / Days to Cover

Biotricity has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biotricity has recently decreased by 44.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biotricity does not currently pay a dividend.

Dividend Growth

Biotricity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.73% of the outstanding shares of Biotricity have been sold short.

Short Interest Ratio / Days to Cover

Biotricity has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biotricity has recently decreased by 44.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Biotricity has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biotricity this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for BTCY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biotricity insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.10% of the stock of Biotricity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.89% of the stock of Biotricity is held by institutions.

BTCY Stock Analysis - Frequently Asked Questions

How have BTCY shares performed this year?

Biotricity's stock was trading at $1.15 at the beginning of 2024. Since then, BTCY shares have decreased by 76.6% and is now trading at $0.2691.
View the best growth stocks for 2024 here.

How were Biotricity's earnings last quarter?

Biotricity, Inc. (OTCMKTS:BTCY) posted its quarterly earnings results on Tuesday, February, 14th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). The company earned $2.46 million during the quarter, compared to analyst estimates of $2.80 million.

When did Biotricity's stock split?

Shares of Biotricity reverse split on Monday, July 3rd 2023. The 1-6 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Biotricity?

Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Biotricity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotricity investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Micron Technology (MU) and Bank of America (BAC).

Company Calendar

• Last Earnings: 2/14/2023
• Today: 11/29/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:BTCY
• CUSIP: N/A
• CIK: 1630113
• Web: www.biotricity.com
• Phone: (650) 832-1626
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,660,000.00
• Net Margins: -163.11%
• Pretax Margin: -163.11%
• Return on Equity: N/A
• Return on Assets: -252.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $12.06 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.67) per share
• Price / Book: -0.10

Miscellaneous

• Outstanding Shares: 24,555,000
• Free Float: 6,963,000
• Market Cap: $6.61 million
• Optionable: Not Optionable
• Beta: 1.22